Lowest Price Guaranteed From USD 4,799
Published
August 2021
Pages
159
View Count
10468
Example Insights
-thumb.PNG) |
 |
 |
 |
-thumb.PNG) |
-thumb.PNG) |
 |
 |
Report Description
The biospecimen CRO market is estimated to be worth around $52 million and is expected to grow at compounded annual growth rate (CAGR) of 16% during the forecast period. Biomedical research is an evolutionary process involving a wide array of research experiments focused on studying diseases and their treatment options; biospecimens are credited as critical components of this process, starting from drug development to clinical trials and epidemiological investigations. Further, in the field of precision medicine, biospecimens act as a link between the biology of a patient and the development of customized therapy. However, procurement and storage of a high quality biospecimen and its analytical evaluation has remained a challenge in the pharmaceutical industry, resulting in delays in research and drug approval timeline. Reliable and efficient traceability of biospecimens demands unique identifiers, advanced data management and quality control systems. Moreover, there are legal and ethical concerns associated with biobanking, and laws and regulations regarding the upkeep of human biospecimens are still evolving.
Over the last few decades, the field of biospecimen research has witnessed significant technological advancements resulting in the procurement of high quality biospecimens for molecular research purposes. In fact, new best practices and improved methods of procurement, processing and storage of biospecimens have also been introduced to the industry. The pharmaceutical industry has seen a significant shift towards outsourcing the bioanalytical services to leverage cost-effective methods and overcome the existing capacity constraints. This shift is evident from the increase in partnership activity focused on expanding the existing capabilities of service providers and offering biospecimen procurement and analytical services. Based on the prevalent trends, we believe that more developers and innovators are likely to rely on the contract research organizations in order to deal with the existing challenges and drive innovation in drug development, thereby, increasing the opportunities for these service providers in the foreseen future.
The “Biospecimen Contract Research Services Market by Therapeutic Area (Oncological Disorders and Other Disorders), Type of Biospecimen for Oncological Studies (FFPE Tissue, Frozen Tissue, Plasma / Serum and Other Biospecimens), Type of Biospecimen for Non-Oncological Studies (Blood Products, Human Tissue and Other Biospecimens), Key Geographical Regions (North America (US and Canada), Europe (Germany, France, Italy, UK, Spain and Other European Countries) and Asia Pacific (China, India, Japan and other Asia-Countries and Rest of the World)): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study on the companies offering research services related to biospecimens. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the current market size and the growth opportunities in the biospecimen contract research services market, over the next decade. Based on different parameters, such as overall human biological sample market, share of commercial biobanks and share of biospecimen contract research service providers, we have provided informed estimates on the evolution of the market for the period 2021-2030. In order to provide a detailed future outlook, year-wise projections of the current and forecasted opportunity have been further segmented across [A] Therapeutic Area (Oncological Disorders and Other Disorders), [B] Type of Biospecimen for Oncological Studies (FFPE, Frozen Tissue, Plasma / Serum and Other Biospecimens), [C] Type of Biospecimen for Non-Oncological Studies (Blood Product, Human Tissue and Other Biospecimens), [D] Key Geographical Regions (North America (US and Canada), Europe (Germany, France, Italy, UK, Spain and Other European Countries) and Asia Pacific (China, India, Japan and other Asia-Countries and Rest of the World). In order to account for the uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the report are backed by a deep understanding of key insights generated from both secondary and primary research. The information presented in this study was also influenced by discussions held with senior stakeholders in this industry. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the biospecimen contract research services market in the short to mid-term, and long term.
Chapter 3 provides a general introduction to biospecimen and their role in the field of drug discovery. It also features brief description of the factors affecting the quality of biospecimen. In addition, it discusses the regulatory guidelines and outsourcing trends in biospecimen research market. The chapter also discusses the future perspectives of the biospecimen contract research services market.
Chapter 4 provides an overview of overall landscape of the companies that claim to offer research services related to biospecimens, including analysis based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, types of blood products offered (plasma, serum, whole blood, blood cells and bone marrow), types of human tissues offered (Formalin-Fixed Paraffin-Embedded, frozen tissue and fresh tissue), types of biofluids offered (urine, saliva, cerebrospinal fluid, swab, synovial fluid, others), types of other biospecimens offered (fecal matter and nucleic acid), types of analytical services offered (histological analysis, target validation, tissue microarray, tumor tissue analysis and cell based assay), types of samples offered (healthy and diseased samples), types of accreditations received and geographical reach (North America, Europe, Asia-Pacific and Rest of the World).
Chapter 5 features a detailed competitiveness analysis of the biospecimen contract research service providers based in North America, Europe and Asia-Pacific, which offer services from their own biorepository or through the network of biorepositories. The companies have been segregated into two peer groups based on the availability of biorepository and compared on the basis of portfolio strength (in terms of number of biospecimens, number of analytical services and number of samples offered), service strength (in terms of number of accreditations and geographical reach), supplier strength (in terms of years of experience in this field and company size).
Chapter 6 tabulated profiles of North America based stakeholders offering biospecimen related services. Each profile features a brief overview of the company, details on its biospecimen related services offered, types of blood products offered, types of human tissues offered, types of other biospecimens offered, types of analytical services offered, types of samples offered, geographical availability of the services, recent developments and an informed future outlook.
Chapter 7 tabulated profiles of Europe and Asia-Pacific based stakeholders offering biospecimen related services. Each profile features a brief overview of the company, details on its biospecimen related services offered, types of blood products offered, types of human tissues offered, types of other biospecimens offered, types of analytical services offered, types of samples offered, geographical availability of the services, recent developments and an informed future outlook.
Chapter 8 features a detailed analysis of the various collaborations and partnerships that have been inked amongst players since 2015. It includes a brief description of the partnership models (including acquisition / merger, service agreement, service alliance, distribution agreement, joint venture and other agreements) adopted by stakeholders in this domain. Further, it comprises of analysis based on year of partnership, type of partnership, type of collaborator, types of services offered, type of biospecimens offered, therapeutic area, region (where both the parties involved in the collaboration are headquartered) and most active players (in terms of number of partnerships).
Chapter 9 is a case study providing information on close to 20 commercial biobanks which claim to offer the procurement services. It features a detailed analysis based on the year of establishment, company size, location of headquarters, types of services offered (sample collection, sample processing, sample logistic / transportation and sample storage), types of biospecimens handled (biofluids, human cells and tissues), therapeutic area (cardiovascular disorders, oncological disorders, neurological disorders, infectious diseases and other therapeutic areas). In addition, it presents a competitiveness analysis of the commercial biobanks based on the availability of their respective biorepositories.
Chapter 10 presents an in-depth analysis of biospecimen contract research service providers. It featured four schematic representations, namely [A] a grid analysis based on the year of establishment and type of analytical services offered, [B] a representation based on the therapeutic area and most active players, [C] an analysis based on the company size and therapeutic area, and [D] a world map representation highlighting the regional distribution of biospecimen research service providers, based on the locations of their biorepositories.
Chapter 11 presents an insightful market forecast analysis, highlighting the likely growth of the biospecimen contract research services market till the year 2030. In order to provide an informed future outlook, our projections have been segmented across [A] Therapeutic Area (Oncological Disorders and Other Disorders), [B] Type of Biospecimen for Oncological Studies (FFPE, Frozen Tissue, Plasma / Serum and Other Biospecimens), [C] Type of Biospecimen for Non-Oncological Studies (Blood Product, Human Tissue and Other Biospecimens), [D] Key Geographical Regions (North America (US and Canada), Europe (Germany, France, Italy, UK, Spain and Other European Countries) and Asia Pacific (China, India, Japan and other Asia-Countries and Rest of the World).
Chapter 12 is a summary of the overall report, which presents insights on the contemporary market trends and the likely evolution of the biospecimen contract research services market in the future.
Chapter 13 contains the interview transcripts of discussions held with representatives of renowned organizations engaged in the CRISPR technology domain. In this chapter, we have presented the insights on our conversation with Ramchandra Rao (Managing Director and Business Development Head, BioSpecimen Solutions) and Oleg Granstrem (Director of Business Development, National BioService)
Chapter 14 is an appendix, that contains tabulated data and numbers for all the figures provided in the report.
Chapter 15 is an appendix that provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Biospecimen
3.3. Importance of Biospecimen in Drug Discovery and Research
3.4. Factors Affecting the Quality of Biospecimen
3.5. Biospecimen Management
3.6. Regulatory Guidelines
3.7. Outsourcing in Biospecimen Research
3.7.1. Role of Contract Research Organizations in Biospecimen Procurement
3.7.2. Types of Services Offered by Contract Research Organizations
3.8. Future Perspective
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Biospecimen Research Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Blood Product(s) Offered
4.2.5. Analysis by Type of Human Tissue(s) Offered
4.2.6. Analysis by Type of Biofluid(s) and Other Biospecimen(s) Offered
4.2.7. Analysis of Type of Analytical Service(s) Offered
4.2.8. Analysis by Type of Sample(s) Offered
4.2.9. Analysis of Accreditation(s) Received
4.2.10. Analysis by Geographical Reach
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Key Parameters
5.4. Competitiveness Analysis: Biospecimen Research Service Providers with Biorepositories
5.4.1. Companies Offering Biospecimen Research Services in North America
5.4.2. Companies Offering Biospecimen Research Services in Europe and Asia-Pacific
5.5. Competitiveness Analysis: Biospecimen Research Service Providers without Biorepositories
5.5.1. Companies Offering Biospecimen Research Services in North America
5.5.2. Companies Offering Biospecimen Research Services in Europe
6. BIOSPECIMEN SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. BioChain Institute
6.2.1. Company Overview
6.2.2. Biospecimen Related Service Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. BioIVT
6.3.1. Company Overview
6.3.2. Biospecimen Related Service Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Creative Bioarray
6.4.1. Company Overview
6.4.2. Biospecimen Related Service Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Discovery Life Sciences
6.5.1. Company Overview
6.5.2. Biospecimen Related Service Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Infinity BiologiX
6.6.1. Company Overview
6.6.2. Biospecimen Related Service Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Precision for Medicine
6.7.1. Company Overview
6.7.2. Biospecimen Related Service Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. PrecisionMed
6.8.1. Company Overview
6.8.2. Biospecimen Related Service Portfolio
6.8.3. Recent Developments and Future Outlook
7. BIOSPECIMEN SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. Medicover
7.2.1. Company Overview
7.2.2. Biospecimen Related Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. National BioService
7.3.1. Company Overview
7.3.2. Biospecimen Related Service Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. REPROCELL
7.4.1. Company Overview
7.4.2. Biospecimen Related Service Portfolio
7.4.3. Recent Developments and Future Outlook
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Biospecimen Research Services: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Collaborator
8.3.4. Analysis by Type of Service(s) Offered
8.3.5. Analysis by Type of Biospecimen(s) Handled
8.3.6. Analysis by Therapeutic Area
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.4. Geographical Analysis
8.4.1. Intercontinental and intracontinental Agreements
9. CASE STUDY: MARKET LANDSCAPE OF COMMERCIAL BIOBANKS
9.1. Chapter Overview
9.2. Commercial Biobanks: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters
9.2.4. Analysis by Types of Service(s) Offered
9.2.5. Analysis by Types of Biospecimen(s) Handled
9.2.6. Analysis by Therapeutic Area
9.3. Company Competitiveness Analysis
9.3.1. Methodology and Key Parameters
9.3.2. Competitiveness Analysis: Commercial Biobanks with Biorepositories
9.3.3. Competitiveness Analysis: Commercial Biobanks without Biorepositories
10. KEY INSIGHTS
10.1. Chapter Overview
10.2 Grid Analysis: Analysis by Year of Establishment and Type of Analytical Service(s) Offered
10.3. Analysis by Company Size and Therapeutic Area
10.4 Most Active Players: Analysis by Therapeutic Area and
10.5. World Map Representation: Analysis by Location of In-House Biorepositories
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Overall Biospecimen Research Services Market, 2021-2030
11.3.1. Biospecimen Research Services Market, 2021-2030: Distribution by Type of Biospecimen
11.3.2. Biospecimen Research Services Market, 2021-2030: Distribution by Therapeutic Area
11.3.3. Biospecimen Research Services Market, 2021-2030: Distribution by Key Geographical Regions
11.3.3.1. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Countries
11.3.3.2. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Type of Biospecimen
11.3.3.3. Biospecimen Research Services Market in North America, 2021-2030: Distribution by Therapeutic Area
11.3.3.4. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Countries
11.3.3.5. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Type of Biospecimen
11.3.3.6. Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Therapeutic Area
11.3.3.4. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Countries
11.3.3.5. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Biospecimen
11.3.3.6. Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area
12. CONCLUSION
12.1. Chapter Overview
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. BioSpecimen Solutions
13.2.1. Overview of Company / Organization
13.2.2. Interview Transcript: Ramachandra Rao, Managing Director and Business Development Head
13.3. National BioService
13.3.1. Overview of Company / Organization
13.3.2. Interview Transcript: Oleg Granstrem, Director of Business Development
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Current Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.2 Executive Summary: Current Landscape of Commercial Biobanks
Figure 2.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Factors Affecting the Quality of Biospecimen
Figure 3.2 Lifecycle of a Biospecimen
Figure 3.3 Clinical Trial related Services offered by CROs
Figure 4.1 Biospecimen Contract Research Service Providers: Distribution by Year of Establishment
Figure 4.2 Biospecimen Contract Research Service Providers: Distribution by Company Size
Figure 4.3 Biospecimen Contract Research Service Providers: Distribution by Location of Headquarters
Figure 4.4 Biospecimen Contract Research Service Providers: Distribution by Type of Blood Product(s) Offered and Type of Sample(s) Offered
Figure 4.5 Biospecimen Contract Research Service Providers: Distribution by Type of Human Tissue(s) Offered
Figure 4.6 Biospecimen Contract Research Service Providers: Distribution by Type of Biofluid(s) Offered
Figure 4.7 Biospecimen Contract Research Service Providers: Distribution by Type of Analytical Service(s) Offered
Figure 4.8 Biospecimen Contract Research Service Providers: Distribution by Type of Sample(s) Offered
Figure 4.9 Biospecimen Contract Research Service Providers: Distribution by Accreditation(s) Received
Figure 4.10 Biospecimen Contract Research Service Providers: Distribution by Type of Analytical Service(s) Offered and Geographical Reach
Figure 5.1 Company Competitiveness Analysis: Biospecimen Research Service Providers based in North America (With Biorepositories)
Figure 5.2 Company Competitiveness Analysis: Biospecimen Research Service Providers based in Europe and Asia-Pacific (With Biorepositories)
Figure 5.3 Company Competitiveness Analysis: Biospecimen Research Service Providers based in North America (Without Biorepositories)
Figure 5.4 Company Competitiveness Analysis: Biospecimen Research Service Providers based in Europe and Asia-Pacific (Without Biorepositories)
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Collaborator
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Service(s) Offered
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Biospecimen(s) Handled
Figure 8.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.7 Partnerships and Collaborations: Distribution of Most Active Players by Number of Partnerships
Figure 8.8 Partnerships and Collaborations: Geographical Analysis
Figure 8.9 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Agreements
Figure 9.1 Commercial Biobanks: Distribution by Year of Establishment
Figure 9.2 Commercial Biobanks: Distribution by Company Size
Figure 9.3 Commercial Biobanks: Distribution by Location of Headquarters
Figure 9.4 Commercial Biobanks: Distribution by Type of Service(s) Offered
Figure 9.5 Commercial Biobanks: Distribution by Type of Biospecimen(s) Handled
Figure 9.6 Commercial Biobanks: Distribution by Therapeutic Area
Figure 9.7 Competitiveness Analysis: Commercial Biobanks with Biorepositories
Figure 9.8 Competitiveness Analysis: Commercial Biobanks without Biorepositories
Figure 10.1 Grid Analysis: Distribution by Year of Establishment and Type of Analytical Services Offered
Figure 10.2 Biospecimen Service Providers: Distribution by Type of Company Size and Therapeutic Area
Figure 10.3 Most Active Players: Distribution by Therapeutic Area
Figure 10.4 World Map Representation: Distribution by Location of In-House Biorepositories
Figure 11.1 Overall Biospecimen Research Services Market, 2021-2030 (USD Million)
Figure 11.2 Biospecimen Research Services Market, 2021-2030: Distribution by Type of Biospecimen (USD Million)
Figure 11.3 Biospecimen Research Services Market, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 11.4 Biospecimen Research Services Market, 2021-2030: Distribution by Key Geographical Regions (USD Million)
Figure 11.5 Biospecimen Research Services Market in North America, 2021-2030: Distribution by Countries (USD Million)
Figure 11.6 Biospecimen Research Services Market in North America, 2021-2030: Distribution by Type of Biospecimen (USD Million)
Figure 11.7 Biospecimen Research Services Market in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 11.8 Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Countries (USD Million)
Figure 11.9 Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Type of Biospecimen (USD Million)
Figure 11.10 Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 11.11 Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Countries (USD Million)
Figure 11.12 Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Biospecimen (USD Million)
Figure 11.13 Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 12.1 Concluding Remarks: Current Biospecimen Contract Research Service Providers Market Landscape Summary
Figure 12.2 Concluding Remarks: Partnerships and Collaborations
Figure 12.3 Concluding Remarks: Market Forecast and Opportunity Analysis
Table 4.1 Biospecimen Research Service Providers: List of Companies
Table 4.2 Biospecimen Contract Research Service Providers: Information on Type of Blood Product(s) Offered
Table 4.3 Biospecimen Contract Research Service Providers: Information on Type of Human Tissue(s) Offered
Table 4.4 Biospecimen Contract Research Service Providers: Information on Type of Biofluid(s) and Other Biospecimen offered
Table 4.5 Biospecimen Contract Research Service Providers: Information on Type of Analytical Service(s) Offered
Table 4.6 Biospecimen Contract Research Service Providers: Information on Type of Sample(s) Offered
Table 4.7 Biospecimen Contract Research Service Providers: Information on Type of Accreditation(s) Received
Table 4.8 Biospecimen Contract Research Service Providers: Information on Geographical Reach
Table 6.1 Biospecimen Service Providers in North America: List of Profiled Companies
Table 6.2 BioChain Institute: Company Snapshot
Table 6.3 Biospecimen Related Service Portfolio
Table 6.4 BioChain Institute: Recent Developments and Future Outlook
Table 6.5 BioIVT: Company Snapshot
Table 6.6 Biospecimen Related Service Portfolio
Table 6.7 BioIVT: Recent Developments and Future Outlook
Table 6.8 Creative Bioarray: Company Snapshot
Table 6.9 Biospecimen Related Service Portfolio
Table 6.10 Creative Bioarray: Recent Developments and Future Outlook
Table 6.11 Discovery Life Sciences: Company Snapshot
Table 6.12 Biospecimen Related Service Portfolio
Table 6.13 Discovery Life Sciences: Recent Developments and Future Outlook
Table 6.14 Infinity BiologiX: Company Snapshot
Table 6.15 Biospecimen Related Service Portfolio
Table 6.16 Infinity BiologiX: Recent Developments and Future Outlook
Table 6.17 Precision for Medicine: Company Snapshot
Table 6.18 Biospecimen Related Service Portfolio
Table 6.19 Precision for Medicine: Recent Developments and Future Outlook
Table 6.20 PrecisionMed: Company Snapshot
Table 6.21 Biospecimen Related Service Portfolio
Table 6.22 PrecisionMed: Recent Developments and Future Outlook
Table 7.1 Medicover: Company Snapshot
Table 7.2 Biospecimen Related Service Portfolio
Table 7.3 Medicover: Recent Developments and Future Outlook
Table 7.4 National BioService: Company Snapshot
Table 7.5 Biospecimen Related Service Portfolio
Table 7.6 National BioService: Recent Developments and Future Outlook
Table 7.7 REPROCELL: Company Snapshot
Table 7.8 Biospecimen Related Service Portfolio
Table 7.9 REPROCELL: Recent Developments and Future Outlook
Table 9.1 Biospecimen Contract Research Service Providers: Partnerships and Collaborations, 2015-2021
Table 9.2 Partnerships and Collaborations: Information on Type of Service(s) Offered, Type of Biospecimens(s) Handled and Therapeutic Area, 2015-2021
Table 10.1 Commercial Biobanks: List of Companies
Table 10.2 Commercial Biobanks: Information on Type of Service(s) Offered
Table 10.2 Commercial Biobanks: Information on Type of Biospecimen(s) Handled
Table 10.3 Commercial Biobanks: Information on Therapeutic Areas
Table 14.1 Biospecimen Contract Research Service Providers: Distribution by Year of Establishment
Table 14.2 Biospecimen Contract Research Service Providers: Distribution by Company Size
Table 14.3 Biospecimen Contract Research Service Providers: Distribution by Location of Headquarters
Table 14.4 Biospecimen Contract Research Service Providers: Distribution by Type of Blood Product(s) Offered and Type of Sample(s) Offered
Table 14.5 Biospecimen Contract Research Service Providers: Distribution by Type of Human Tissue(s) Offered
Table 14.6 Biospecimen Contract Research Service Providers: Distribution by Type of Biofluid(s) Offered
Table 14.7 Biospecimen Contract Research Service Providers: Distribution by Type of Analytical Service(s) Offered
Table 14.8 Biospecimen Contract Research Service Providers: Distribution by Type of Sample(s) Offered
Table 14.9 Biospecimen Contract Research Service Providers: Distribution by Accreditation(s) Received
Table 14.10 Biospecimen Contract Research Service Providers: Distribution by Type of Analytical Service(s) Offered and Geographical Reach
Table 14.11 Partnerships and Collaborations: Distribution by Year of Partnership
Table 14.12 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.13 Partnerships and Collaborations: Distribution by Type of Collaborator
Table 14.14 Partnerships and Collaborations: Distribution by Type of Service(s) Offered
Table 14.15 Partnerships and Collaborations: Distribution by Type of Biospecimen(s) Handled
Table 14.16 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 14.17 Partnerships and Collaborations: Distribution of Most Active Players by Number of Partnerships
Table 14.18 Partnerships and Collaborations: Geographical Analysis
Table 14.19 Partnerships and Collaborations: Distribution Intercontinental and Intracontinental Agreements
Table 14.20 Commercial Biobanks: Distribution by Year of Establishment
Table 14.21 Commercial Biobanks: Distribution by Company Size
Table 14.22 Commercial Biobanks: Distribution by Location of Headquarters
Table 14.23 Commercial Biobanks: Distribution by Types of Service(s) Offered
Table 14.24 Commercial Biobanks: Distribution by Types of Biospecimen(s) Handled
Table 14.25 Commercial Biobanks: Distribution by Therapeutic Area
Table 14.26 Biospecimen Service Providers: Distribution by Type of Company Size and Therapeutic Area
Table 14.27 Overall Biospecimen Research Services Market, 2021-2030 (USD Million)
Table 14.28 Biospecimen Research Services Market, 2021-2030: Distribution by Type of Biospecimen (USD Million)
Table 14.29 Biospecimen Research Services Market, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 14.30 Biospecimen Research Services Market, 2021-2030: Distribution by Key Geographical Regions (USD Million)
Table 14.31 Biospecimen Research Services Market in North America, 2021-2030: Distribution by Countries (USD Million)
Table 14.32 Biospecimen Research Services Market in North America, 2021-2030: Distribution by Type of Biospecimen (USD Million)
Table 14.33 Biospecimen Research Services Market in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 14.34 Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Countries (USD Million)
Table 14.35 Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Type of Biospecimen (USD Million)
Table 14.36 Biospecimen Research Services Market in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 14.37 Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Countries (USD Million)
Table 14.38 Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Biospecimen (USD Million)
Table 14.39 Biospecimen Research Services Market in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
The following companies and organizations have been mentioned in the report.
Source 1: www.ispecimen.com/for-researchers/
Source 2: www.contractpharma.com/issues/2007-11/view_features/bioanalytical-outsourcing/
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES